PY2013134A - Métodos para el tratamiento de enfermedades relacionadas con tnfa - Google Patents
Métodos para el tratamiento de enfermedades relacionadas con tnfaInfo
- Publication number
- PY2013134A PY2013134A PY202002013134A PY2013134A PY2013134A PY 2013134 A PY2013134 A PY 2013134A PY 202002013134 A PY202002013134 A PY 202002013134A PY 2013134 A PY2013134 A PY 2013134A PY 2013134 A PY2013134 A PY 2013134A
- Authority
- PY
- Paraguay
- Prior art keywords
- tnf
- methods
- tnfa
- treatment
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de una enfermedad relacionada con TNF-α mediante la administración subcutánea de un anticuerpo que se une a TNF-α (anticuerpo anti-TNF-α) o fragmento de unión a antígeno del mismo. En comparación con la inyección intravenosa, el método de tratamiento, la composición, el kit o el uso de acuerdo con la presente invención, ofrece la ventaja de mejorar la satisfacción del paciente, al mejorar su comodidad y calidad de vida, es decir, al reducir el tiempo requerido para la administración y disminuir la estancia del paciente en el hospital.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190023769 | 2019-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY2013134A true PY2013134A (es) | 2020-11-30 |
Family
ID=72239651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY202002013134A PY2013134A (es) | 2019-02-28 | 2020-02-27 | Métodos para el tratamiento de enfermedades relacionadas con tnfa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220153828A1 (es) |
| JP (1) | JP7577674B2 (es) |
| KR (1) | KR20200105439A (es) |
| AR (1) | AR118191A1 (es) |
| BR (1) | BR112021016913A2 (es) |
| CA (1) | CA3130921A1 (es) |
| PY (1) | PY2013134A (es) |
| TW (1) | TW202045137A (es) |
| UY (1) | UY38595A (es) |
| WO (1) | WO2020175954A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3479819B1 (en) | 2016-06-30 | 2024-01-24 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| KR20250031013A (ko) * | 2023-08-23 | 2025-03-06 | (주)셀트리온 | TNFα 관련 질환을 치료하는 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817619A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| DK1919951T3 (en) * | 2005-08-04 | 2015-02-16 | Janssen Biotech Inc | Anti-tnf-alpha antibodies and methods of use |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| MX361242B (es) * | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
| EP3078675A1 (en) * | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| EP3479819B1 (en) * | 2016-06-30 | 2024-01-24 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| MX2019011786A (es) * | 2017-03-30 | 2020-02-10 | Glofish Llc | Tiburon arcoiris transgenico. |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
-
2020
- 2020-02-26 AR ARP200100519A patent/AR118191A1/es unknown
- 2020-02-27 PY PY202002013134A patent/PY2013134A/es unknown
- 2020-02-27 UY UY0001038595A patent/UY38595A/es not_active Application Discontinuation
- 2020-02-27 TW TW109106508A patent/TW202045137A/zh unknown
- 2020-02-28 JP JP2021550084A patent/JP7577674B2/ja active Active
- 2020-02-28 US US17/430,628 patent/US20220153828A1/en active Pending
- 2020-02-28 BR BR112021016913A patent/BR112021016913A2/pt unknown
- 2020-02-28 CA CA3130921A patent/CA3130921A1/en active Pending
- 2020-02-28 KR KR1020200024817A patent/KR20200105439A/ko active Pending
- 2020-02-28 WO PCT/KR2020/002886 patent/WO2020175954A1/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20220153828A1 (en) | 2022-05-19 |
| AR118191A1 (es) | 2021-09-22 |
| KR20200105439A (ko) | 2020-09-07 |
| TW202045137A (zh) | 2020-12-16 |
| WO2020175954A1 (ko) | 2020-09-03 |
| BR112021016913A2 (pt) | 2021-11-03 |
| CA3130921A1 (en) | 2020-09-03 |
| UY38595A (es) | 2020-09-30 |
| JP7577674B2 (ja) | 2024-11-05 |
| JP2022521996A (ja) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023002206A2 (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| EA201892190A1 (ru) | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| CL2022001984A1 (es) | Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| PY2013134A (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfa | |
| CO2020002117A2 (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfα | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| MX2023002843A (es) | Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios. | |
| CL2025000215A1 (es) | Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma | |
| EA202190504A1 (ru) | Способы лечения псориаза | |
| CL2023002914A1 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| MX2023004034A (es) | Métodos de tratamiento de la dermatomiositis. | |
| MX2025000385A (es) | Metabolitos de belumosudil y usos de los mismos en el tratamiento de la enfermedad cronica del injerto contra el hospedero | |
| WO2020022438A8 (ja) | 網膜線維化を伴う眼疾患の処置剤 | |
| NZ760588B2 (en) | Methods for Treating TNFa-Related Diseases | |
| MX2022002947A (es) | Avocatina b para el tratamiento de enfermedades y afecciones. | |
| EA202090894A1 (ru) | Дозирование и введение антител против c5 для лечения пациентов с мембранопролиферативным гломерулонефритом |